Idorsia Ltd (OTCMKTS:IDRSF) Receives $23.00 Average PT from Brokerages

Shares of Idorsia Ltd (OTCMKTS:IDRSFGet Rating) have been given a consensus rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $23.00.

IDRSF has been the topic of a number of research analyst reports. Jefferies Financial Group cut Idorsia from a “buy” rating to a “hold” rating in a report on Wednesday. Credit Suisse Group downgraded shares of Idorsia from an “outperform” rating to a “neutral” rating in a report on Thursday, November 10th. JPMorgan Chase & Co. cut their price objective on Idorsia from CHF 17 to CHF 15 and set a “neutral” rating for the company in a research report on Tuesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered Idorsia from a “buy” rating to a “hold” rating in a research report on Friday, October 21st.

Idorsia Stock Up 0.3 %

OTCMKTS IDRSF opened at $18.33 on Wednesday. Idorsia has a twelve month low of $11.62 and a twelve month high of $23.84. The business has a 50-day moving average price of $15.23 and a 200-day moving average price of $14.50.

Idorsia Company Profile

(Get Rating)

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

Featured Articles

Analyst Recommendations for Idorsia (OTCMKTS:IDRSF)

Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with's FREE daily email newsletter.